Various preclinical and clinical studies have also evaluated the effect of EGFR-TKIs in combination with other chemotherapeutic agents and therapies interfering with the proteins of downstream EGFR signaling in triple-negative breast cancer (TNBC) [102,103]. The gene discussed is EGFR; the disease is triple-negative breast carcinoma.